Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing <i>Klebsiella pneumoniae</i> bloodstream infection: a retrospective cohort study.

Specifically, after excluding patients with CKD, ceftazidime/avibactam-adjusted dosage was not associated with the main outcome (HR 4.07, 95% CI 0.59–27.74, P = 0.152), while, after excluding patients with AKI (and therefore including those receiving a reduced dosage of ceftazidime/avibactam due to CKD), there was a trend towards significance (HR 5.16, 95% CI 0.87–30.56, P = 0.071).

also in 1,011 other papers